Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1)

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 3, 1999, Pages 1427-1433

  Hillard, Cecilia J ^a   Manna, Sukumar ^a   Greenberg, Marcie J ^a   Dicamelli, Ralph ^a   Ross, Ruth A ^b   Stevenson, Lesley A ^b   Murphy, Vicki ^b   Pertwee, Roger G ^b   Campbell, William B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AMIDE; ANANDAMIDE; ARACHIDONYL 2 CHOROETHYLAMIDE; ARACHIDONYLCYCLOPROPYLAMIDE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ETHANOLAMINE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL;

ADENYLATE CYCLASE; ANIMALS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; BODY TEMPERATURE; CANNABINOIDS; CEREBELLUM; CHO CELLS; CRICETINAE; CYCLOHEXANOLS; ELECTRIC STIMULATION; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; KINETICS; MALE; MICE; MICE, INBRED ICR; MICE, INBRED STRAINS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NEURONS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RECOMBINANT PROTEINS; TRANSFECTION; VAS DEFERENS;

EID: 0033060910     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Adams IB, Compton DR and Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217.
2. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Peccue F, Lupker J, Maffrand J-P, Fur GL and Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by inaulin or insulin-like growth factor 1. J Biol Chem 272:22330-22339.
3. Breivogel C, Sim L and Childers S (1997) Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 282:1632-1642.
4. Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR and Yamamura HI (1997) Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur J Pharmacol 338:295-298.
5. 50) of an enzymatic reaction. Biochem Pharmacol 22:711-715.
6. Childers S, Sexton T and Roy M (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 47:711-715.
7. Desarnaud F, Cadas H and Piomelli D (1995) Anandamide amidohydrolase activity in rat brain microsomes. J Biol Chem 270:6030-6035.
8. Deutsch D and Chin S (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46791-796.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Wash DC) 258:1946-1949.
10. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178.
11. Edgemond WS, Hillard CJ, Falck JR, Kearn CS and Campbell WB (1998) Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): Their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54:180-188.
12. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
13. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, DeCosta BR and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
14. Hillard C and Campbell W (1997) Biochemistry and pharmacology of arachidonylethanolamine, a putative endogenous cannabinoid. J Lipid Res 38:2383-2398.
15. Hillard CJ, Edgemond WS and Campbell WB (1995) Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: Application to anandamide. J Neurochem 64:677-683.
16. Hillard C, Wilkison D, Edgemond W and Campbell W (1995) Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta 1257:249-256.
17. Huffman JW, Yu S, Liddle J, Wiley JL, Abood ME, Martin BR and Aung MM (1998) 1-Deoxy-1′,1′-dimethylalkyl-Δ8-THC derivatives: Selective ligands for the CB2 receptor. 1998 Symposium on the Cannabinoids, La Grande Motte, France, International Cannabinoid Research Society, Burlington, VT.
18. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD and Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39:3875-3877.
19. Kearn CS and Hillard CJ (1998) Evidence for peripheral-type cannabinoid receptors (CB2) on rat microglial cells. NIDA Res Monogr Ser 178:93.
20. Khanolkar AD, Abadji V, Lin S, Hill WAG, Taha G, Abouzid K, Meng Z, Fan P and Makryannis A (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 39:4514-4519.
21. Kuster J, Stevenson J, Ward S, D'Ambra T and Haycock D (1993) Aminoalkylindole binding in rat cerebellum: Selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 264:1352-1363.
22. Mackie K, Devane WA and Hille B (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44:498-503.
23. Matsuda LA (1997) Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 11:143-166.
24. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
25. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
26. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
27. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R and Corbett AD (1992) Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 105:980-984.
28. Pertwee R, Stevenson L and Griffin G (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol 110:1483-1490.
29. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinex S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC and LeFur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letts 350:240-244.
30. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière J-C and Le Fur G (1998) SR 144528, the first potent and selective antagonist of the CB2 cannà binoid receptor. J Pharmacol Exp Ther 284:644-650.
31. Selley D, Stark S, Sim L and Childers S (1996) Cannabinoid receptor stimulation of guanosine-5′-O-3-[35S]thio)triphsophate binding in rat brain membranes. Life Sci 59:659-668.
32. Showalter VM, Compton DR, Martin BR and Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype specific ligands. J Pharmacol Exp Ther 278:989-999.
33. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M and Metters KM (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352-361.
34. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R and Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227.
35. Wieland T and Jakobs K (1994) Measurement of receptor-stimulated guanosine 5′-O-(γ-thio)triphosphate binding by G proteins. Methods Enzymol 237:3-26.
36. Willoughby KA, Moore SF, Martin BR and Ellis EF (1997) The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282:243-247.